The agreement will allow VIVO to sell its medicinal cannabis flower, oil and other products to Australian patients through approved channels.
The regulatory import permits required to enable the first shipment of product under the agreement have been granted by the Australia Office of Drug Control.
Burleigh Heads expects to import the first shipment of VIVO products in June, subject to receipt of a Canadian export permit.
“We are very excited to announce the signing of this distribution agreement, which will give us increased exposure in the Australian market and enhance consumer awareness of our brand and products,” VIVO CEO Barry Fishman stated.
“Burleigh Heads is a strong advocate for improving patient access to safe cannabis medicines and, together with its affiliate, CDA Clinics Australia, is a leader in providing Australian patients with channels through which to acquire high-quality cannabis products,” Fishman added.